Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Shonan iPark Begins Pilot Study to Build iPS Cell Donation Platform
February 3, 2021
- Hokkaido Univ., PuREC, Mochida Launch Joint Research on Novel Treatment for Spine-Related Diseases
February 3, 2021
- Nichi-Iko Closes Acquisition of Teva Takeda’s Generic Biz
February 2, 2021
- Ono Logs 4.3% Sales Growth in April-December, Opdivo Jumps
February 2, 2021
- Astellas Returns Rights to Prostate Cancer Med to US Firm
February 2, 2021
- Sumitomo Dainippon to Invest Up to US$20 Million in US Venture Fund Focused on Digital Health
February 2, 2021
- Shuhei Sekiguchi to Become Janssen Japan Chief on March 1
February 2, 2021
- Sosei Ties Up with UK CRO to Identify Lead Compounds in Neurological Diseases
February 2, 2021
- Shionogi Sees Double-Digit Sales Decline in April-December as Infectious Disease Meds Suffer
February 2, 2021
- Astellas Sees Growth of Evrenzo after 14-Day Prescription Limit Lifted: EVP
February 1, 2021
- FunPep Initiates Development of New IL-23 Antibody-Inducing Peptide
February 1, 2021
- Teijin to Acquire Fujifilm's J-TEC for Up to 21.6 Billion Yen
February 1, 2021
- Asahi Kasei Pharma Licenses Chronic Pain Drug AK1780 to Eli Lilly
February 1, 2021
- Daiichi Sankyo’s Revenue Down 2.4% in April-December as Mainstays Flounder at Home
February 1, 2021
- Astellas’ 9-Month Earnings Stumble on Celecox Generic Erosion, Sales Pact Terminations
February 1, 2021
- FDA Delays Decision for Biogen’s Aducanumab to June 7
February 1, 2021
- Sumitomo Dainippon Logs Double-Digit Growth on Diabetes Meds: April-December
January 29, 2021
- Fujifilm Toyama Chemical Files Radiopharmaceutical F-1614
January 29, 2021
- Pfizer Japan Files Somatrogon for Growth Hormone Deficiency
January 29, 2021
- Relumina Submitted for Endometriosis Use in Japan: ASKA
January 29, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…